Publications by authors named "Axel Merseburger"

Claim this Profile
C
Comparative Survival in Metastatic Hormone-sensitive Prostate Cancer by Volume of Disease and Timing of Metastasis: A Living Network Meta-analysis.
Irbaz Bin Riaz, Syed Arsalan Ahmed Naqvi, Kunwer Sufyan Faisal, Huan He, Kaneez Zahra Rubab Khakwani, Axel S Merseburger

Eur Urol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economics, Ergonomics, Effectiveness: A Monocentric Comparison of Single-Use vs. Reusable Flexible Ureteroscopes in Challenging Kidney Stone Cases.
Tomasz Ozimek, Karsten Günzel, Natasza Galuszka-Ozimek, Judith Riccarda Wießmeyer, Benedikt Becker, Axel S Merseburger

Aktuelle Urol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Not Available].
Angelika Borkowetz, Axel S Merseburger

Aktuelle Urol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[New Prostate Cancer Guideline: Is Biopsy of PI-RADS 3 Lesions Meaningful? The Role of Multiparametric MRI-Ultrasound Fusion Biopsy in Detecting Clinically Significant Prostate Cancer].
Paul Schildhauer, Marten Müller, Axel S Merseburger, Alexander Fürschke, Yannic Elser

Aktuelle Urol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using ChatGPT-4 for Lay Summarization in Prostate Cancer Research to Advance Patient-Centered Communication: Large-Scale Generative AI Performance Evaluation.
Emily Rinderknecht, Simon U Engelmann, Veronika Saberi, Clemens Kirschner, Anton P Kravchuk, Axel S Merseburger

J Med Internet Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to Parth Aphale, Shashank Dokania, Himanshu Shekhar's Letter to the Editor re: Bahl A, Chilelli A, Faria R, et al. Association between major cardiovascular events and abiraterone acetate compared to enzalutamide in patients with metastatic castration-resistant prostate cancer: a post hoc analysis of the EVADE study. World J Urol 43:465. https://doi.org/10.1007/s00345-025-05841-9.
Amit Bahl, Andrew Chilelli, Rita Faria, Nigel Rozario, Robert Snijder, Axel S Merseburger

World J Urol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apalutamide in Patients with High Burden of Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of TITAN.
Alejo Rodriguez-Vida, Angel Borque, Fernando Lopez-Campos, Alvaro Juarez Soto, Beatriz Garcillan, Axel S Merseburger

Eur Urol Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CONTACT-02: limited clinical benefit and a suboptimal control group - Authors' reply.
Neeraj Agarwal, Axel S Merseburger, Svetlana Andrianova, Arun A Azad

Lancet Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guiding first-line treatment decisions in advanced urothelial carcinoma: a global survey.
Enrique Grande, Joaquim Bellmunt, Syed A Hussain, Mubarak M Al Mansour, Aristotle Bamias, Axel S Merseburger

Oncologist· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Trajectories in Metastatic Hormone-sensitive Prostate Cancer: A PIONEER+ Big Data Analysis.
Rossella Nicoletti, Alex Qinyang Liu, Susan Evans-Axelsson, Asieh Golozar, Katharina Beyer, Axel S Merseburger

Eur Urol Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prostate-specific Antigen Response as a Prognostic Factor for Overall Survival in Patients with Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors: A Systematic Review and Meta-analysis.
Marcin Miszczyk, Tamás Fazekas, Paweł Rajwa, Akihiro Matsukawa, Ichiro Tsuboi, Axel Merseburger

Eur Urol Focus· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
oDigital pathology biomarkers for guiding radiotherapy-based treatment concepts in prostate cancer - a systematic review and expert consensus.
Constantinos Zamboglou, William De Doncker, Andreas Thomas Christoforou, Stefano Arcangeli, Alejandro Berlin, Axel S Merseburger

Radiother Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Not Available].
Axel S Merseburger, Angelika Borkowetz

Aktuelle Urol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Not Available].
Friederike Praus, Axel S Merseburger, Daniar Osmonov, Marie Christine Roesch

Aktuelle Urol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between major cardiovascular events and abiraterone acetate compared to enzalutamide in patients with metastatic castration-resistant prostate cancer: a post hoc analysis of the EVADE study.
Amit Bahl, Andrew Chilelli, Rita Faria, Nigel Rozario, Robert Snijder, Axel S Merseburger

World J Urol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glans necrosis following penile procedures: a systematic review of etiology, frequency, and management.
Berk Hazir, Axel Stuart Merseburger, Marie Christine Roesch, Daniar Osmonov

Int J Impot Res· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial.
Neeraj Agarwal, Arun A Azad, Joan Carles, Nobuaki Matsubara, Stéphane Oudard, Axel S Merseburger

Lancet Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ultralow Prostate-specific Antigen Nadir After Apalutamide: Outcomes in Synchronous Versus Metachronous Metastatic Hormone-sensitive Prostate Cancer.
Mike Wenzel, Thomas Steuber, Carolin Siech, Maximilian Kriegmair, Benedikt Hoeh, Axel S Merseburger

Eur Urol Open Sci· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Making prostate cancer research accessible: chatGPT-4 as a tool to enhance lay communication].
Maximilian Haas, Veronika Saberi, Christopher Gossler, Anna Schmelzer, Anton Kravchuk, Axel S Merseburger

Urologie· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Androgen receptor-targeted therapies - avoid clinically relevant interactions].
Hans-Peter Lipp, Gunhild von Amsberg, Axel S Merseburger, Steffen Rausch, Tilman Schöning

Aktuelle Urol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Androgen Receptor Pathway Inhibitor Monotherapy in Prostate Cancer: Safety, Oncologic Outcomes, and Quality of Life-A Systematic Review and Meta-analysis.
Tamás Fazekas, Marcin Miszczyk, Alexander Giesen, Tamás Kói, Fabio Zattoni, Axel S Merseburger

Eur Urol Focus· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Comparison of Ultrasound and Magnetic Resonance Imaging in Diagnosing a Penile Fracture: A Retrospective Data Analysis].
Svenja K Morische, Alexander Fürschke, Nils Gilbert, Daniar Osmonov, Axel S Merseburger

Aktuelle Urol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Gender-/Sex-Specific Differences in Clinical Trials in Uro-Oncology].
Marie Christine Roesch, Lea Sophie Lütje, Nils Gilbert, Axel Stuart Merseburger, Daniar Osmonov

Aktuelle Urol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular Risks and Survival with Abiraterone vs Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer in Germany: AVENGER Study.
Axel S Merseburger, Eugen Dornstauder, Carsten-Henning Ohlmann, Armen Aprikian, Sophia Junker

Adv Ther· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Attributes and Health Care Resource Utilization of Patients on Enzalutamide or Abiraterone for Metastatic Castration-Resistant Cancer in England.
Amit Bahl, Rita Faria, Axel S Merseburger, Gert Attard, Robert Snijder

JCO Oncol Pract· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis